Studies carried out in vitro and in patients’ sample specimens provided evidence that ABCB5-expressing cells selectively survive when melanoma cells are exposed to melanoma chemotherapeutics, including vemurafenib, the BRAF inhibitor used for treatment of BRAF V600E melanomas [217]. This evidence concerns the gene BRAF and melanoma.